KRAS Kickers

Two recent perspectives in The Oncologist and European Journal of Cancer offer complementary ways of examining the evolving relationship between RAS inhibition and radiation therapy in pancreatic ductal adenocarcinoma (PDAC). Michael Chuong and Eileen O'Reilly explore emerging preclinical evidence that RAS inhibition can enhance radiation response, including ferroptosis-associated radiosensitization. Their discussion also extends into the broader consequences of RAS inhibition for stromal architecture, immune populations, and the tumor microenvironment. Overlapping gastrointestinal toxicities and the potential for normal-tissue radiosensitization also introduce important considerations for the safe integration of these therapies. As systemic therapies become more effective, durable local disease control may assume greater clinical significance. Susannah Ellsworth and Timothée Olivier approach the question through the history and design of radiation trials in PDAC, where improvements in local control have not consistently translated into overall survival benefit. Their perspective examines the limitations of historical comparisons, evolving systemic standards, radiation dose escalation, patient selection, and the need for clinical trials capable of establishing meaningful incremental benefit. They caution that unless radiation trial designs evolve alongside advances in systemic therapy, radiation risks becoming further marginalized in PDAC treatment. The opportunity for radiation to become more consequential as systemic therapy advances, as envisioned by Chuong and O'Reilly, is inseparable from Ellsworth and Olivier's challenge to ensure its continued clinical relevance through evolving trial designs. RAS inhibition does not operate within an isolated molecular pathway. Suppression of oncogenic signaling can reshape macrophage populations, immune infiltration, fibroblast behavior, and extracellular matrix organization. Some of these changes may enhance therapeutic response, while others may contribute to adaptation and persistence. The more effectively the oncogenic driver is targeted, the more consequential the biology that survives it may become. SBRT brings a distinctive spatial dimension to this challenge. Its capacity for precise local ablation, delivered over a limited number of fractions with the potential to reduce radiation-associated immune-cell depletion, creates an opportunity to integrate complementary interventions across tumor-intrinsic signaling, stromal architecture, and immune biology, extending the therapeutic investigation beyond the irradiated lesion and into the biological conditions that shape residual disease. An example is already emerging in locally advanced and borderline resectable PDAC through the Washington University clinical and translational program. Following induction chemotherapy, adaptive SBRT at 50 Gy in five fractions was combined with concurrent and adjuvant defactinib, a FAK/PYK2 inhibitor, in a phase I/II study (NCT04331041). Among 36 patients receiving the combination, reported one-year outcomes included 80% local control, 76% distant-metastasis-free PFS, 71% PFS, and 94% overall survival. The regimen was well tolerated, with no grade 4 or higher toxicities reported. The distant-disease findings are particularly interesting in a disease where metastatic progression frequently limits the clinical consequences of effective local treatment. Single-cell RNA sequencing of pre- and post-treatment tumor biopsies demonstrated FAK pathway repression and signatures of immune activation in both PDAC cells and tumor-infiltrating immune cells, connecting the clinical observations with changes in tumor ecosystem biology. The study also generated an intriguing exploratory observation involving subsequent surgical management, with differences in observed overall survival according to resection status following SBRT and defactinib. This adds another dimension to the relationship between treatment response, patient selection, and the evolving role of surgery following induction therapy and local treatment. The relatively rapid evolution of this program is particularly relevant to Ellsworth and Olivier's broader challenge: how radiation oncology can move beyond conventional approaches to local treatment and develop biologically informed clinical trials that remain meaningful as systemic therapy advances. Building on the initial clinical and single-cell translational findings, the subsequent randomized phase II investigation (NCT07126158) retains adaptive SBRT at 50 Gy in five fractions while incorporating avutometinib alongside defactinib, extending the biological strategy to complementary RAF/MEK and FAK/PYK2 pathway modulation. The study compares SBRT alone with the triplet combination. Its randomized design, incorporating an SBRT-only control arm and serial tissue assessments, creates an opportunity to examine clinical outcomes alongside treatment-induced changes in oncogenic signaling, stromal interactions, and immune biology. The protocol incorporates progression-free survival assessment in the experimental arm, together with evaluation of local control, distant-metastasis PFS, stromal density, MAPK inhibition, and the tumor immune microenvironment. This progression suggests an emerging adaptive therapeutic envelope around radiation: a coordinated approach in which spatially precise local treatment is integrated with complementary interventions targeting signaling dependencies, stromal interactions, immune adaptation, and the biological conditions supporting residual disease. The questions now extend into the geography, ecology, and evolution of PDAC: where disease persists and recurs, how tumor cells and their surrounding tissue ecosystems respond to therapeutic pressure, and whether complementary RAF/MEK and FAK/PYK2 modulation can influence distant progression, surgical selection, treatment sequencing, and the durability of disease control. Attached infographics: localized PDAC radiation therapy and the adaptive therapeutic envelope across PDAC modalities. @MikeChuongMD @EileenMOReilly @Timothee_MD @free_radical28 @WashUMedRadOnc @DeNardoLabWUSM @adapthyun @JulieSchwarz14 @danp